作者
Rodrigo D Carvalho, Natalia Breyner, Zelia Menezes-Garcia, Nubia M Rodrigues, Luisa Lemos, Tatiane U Maioli, Danielle da Gloria Souza, Denise Carmona, Ana MC de Faria, Philippe Langella, Jean-Marc Chatel, Luis G Bermúdez-Humarán, Henrique CP Figueiredo, Vasco Azevedo, Marcela S de Azevedo
发表日期
2017/12
期刊
Microbial Cell Factories
卷号
16
页码范围
1-11
出版商
BioMed Central
简介
Background
Mucositis is one of the most relevant gastrointestinal inflammatory conditions in humans, generated by the use of chemotherapy drugs, such as 5-fluoracil (5-FU). 5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great discomfort. As current therapy drugs presents limitations in alleviating mucositis symptoms, alternative strategies are being pursued. Recent studies have shown that the antimicrobial pancreatitis-associated protein (PAP) has a protective role in intestinal inflammatory processes. Indeed, it was demonstrated that a recombinant strain of Lactococcus lactis expressing human PAP (LL-PAP) could prevent and improve murine DNBS-induced colitis, an inflammatory bowel disease (IBD) that causes severe inflammation of the colon. Hence, in this study we sought to evaluate the protective effects of …
引用总数
201720182019202020212022202320247988121174